MARKET

ADCT

ADCT

ADC Therapeutics
NYSE

Real-time Quotes | Nasdaq Last Sale

20.45
-0.59
-2.80%
After Hours: 20.45 0 0.00% 16:00 07/27 EDT
OPEN
21.03
PREV CLOSE
21.04
HIGH
21.24
LOW
20.15
VOLUME
403.00K
TURNOVER
--
52 WEEK HIGH
53.35
52 WEEK LOW
20.01
MARKET CAP
1.57B
P/E (TTM)
-5.9188
1D
5D
1M
3M
1Y
5Y
Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $51
Morgan Stanley analyst Matthew Harrison maintains ADC Therapeutics (NYSE:ADCT) with a Overweight and lowers the price target from $53 to $51.
Benzinga · 07/16 12:03
--Morgan Stanley Adjusts Price Target on ADC Therapeutics to $51 From $53, Maintains Overweight Rating
MT Newswires · 07/16 11:05
BRIEF-ADC Therapeutics Announces Encouraging Interim Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine Presented At The 16Th Annual International Conference On Malignant Lymphoma
reuters.com · 06/22 14:55
ADC Therapeutics updates interim data in mid-stage Hodgkin lymphoma study
ADC Therapeutics ([[ADCT]] -1.0%) has announced updated interim results from the ongoing pivotal Phase 2 clinical trial of antibody-drug conjugate, camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma.The open-label,
Seekingalpha · 06/22 14:28
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
LAUSANNE, Switzerland, Jun 22, 2021--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that upda...
Business Wire · 06/22 13:55
ADC Therapeutics Reports 'Encouraging' Interim Results for Camidanlumab Tesirine in Phase 2 Lymphoma Trial
MT Newswires · 06/22 13:17
Bristol's up to $3B deal with Eisai puts antibody drug conjugates in the spotlight
Dr_Microbe/iStock via Getty Images Today's up to $3B development and commercialization deal from Bristol-Myers Squibb (BMY) for Eisai's (ESALY) for MORAb-202 is putting antibody drug conjugates ("ADCs"), which some feel is the
Seekingalpha · 06/18 15:59
ADC Therapeutics reports updated Zynlonta data in blood cancer trials
ADC Therapeutics (ADCT) announces that posters on four Zynlonta (loncastuximab tesirine-lpyl) clinical trials were presented at the 16th Annual International Conference on Malignant Lymphoma ((ICML)). In Phase 2 LOTIS-2 trial
Seekingalpha · 06/18 11:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADCT. Analyze the recent business situations of ADC Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADCT stock price target is 47.25 with a high estimate of 55.00 and a low estimate of 37.00.
EPS
Institutional Holdings
Institutions: 62
Institutional Holdings: 33.37M
% Owned: 43.49%
Shares Outstanding: 76.72M
TypeInstitutionsShares
Increased
16
2.97M
New
18
352.32K
Decreased
12
1.30M
Sold Out
11
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.04%
Pharmaceuticals & Medical Research
-0.18%
Key Executives
Chairman/Director
Ron Squarer
Chief Executive Officer/Director
Chris Martin
Vice Chairman/Chief Financial Officer/Executive Vice President/Director/Primary Contact
Michael Forer
Finance Director
Stephane Henchoz
Senior Vice President
Patrick Van Berkel
Other
Jennifer Herron
Director
Peter Corr
Director
Peter Hug
Director
Viviane Monges
No Data
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Webull offers kinds of ADC Therapeutics SA stock information, including NYSE:ADCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADCT stock methods without spending real money on the virtual paper trading platform.